Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention

Research Group

Prostate and Urologic Cancer

Status

Recruiting

NCT ID

NCT04375813

eRapa (encapsulated rapamycin) will be investigated for secondary prevention in patients with diagnosed non-muscle invasive bladder cancer (NMIBC) through a phase II double-blind randomized controlled trial of long-term (one year) prevention with eRapa versus placebo. The primary hypothesis is that eRapa decreases the risk of cancer relapse for patients with NMIBC. Secondary hypotheses are that eRapa can improve certain immune parameters and improve cognition and physical function without adversely affecting patient-reported outcomes and quality of life.

Intervention

Placebos, eRapa

Condition

Non-muscle Invasive Bladder Cancer

Investigators

Robert S Svatek, MD, MSC, Robert S Svatek, MD, Yair Lotan, MD, Jessie Williams, Donna Mitchell, Fred Norton, BS

See list of participating sites